New HPV vaccine attempts to go global

Article

Global News

GlaxoSmithKline is trying to obtain prequalification from the World Health Organization (WHO) for its new human papillomavirus (HPV) vaccine, Cervarix. Cervarix has already been approved in Europe, and is under review in the US.

If WHO grants the prequalification, then United Nations groups like UNICEF can distribute the vaccine to developing nations. Cervarix, similar to Merck's Gardasil, can substantially reduce the risk of cervical cancer, if given to girls before they become sexually active.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.